Skip to content

The Effects of Topical St Johns Wort Application in Patients with Plaque Type Psoriasis vulgaris

Evaluation of TNFa Levels in Psoriatic Plaque Tissue after topical St Johns Wort (Hypericum perforatum L) Application in Patients with Plaque Type Psoriasis vulgaris

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT201503173106N24
Enrollment
40
Registered
2015-05-03
Start date
2011-02-17
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Plaque Psoriasis. Psoriasis vulgaris

Interventions

Intervention 1: Herbal ointment containing 5% Hypericum perfuratum extract in Vaseline base was used on lesions of one side of the body twice daily. Intervention 2: Placebo ointment in Vaseline base
Treatment - Drugs
Placebo
Herbal ointment containing 5% Hypericum perfuratum extract in Vaseline base was used on lesions of one side of the body twice daily.
Placebo ointment in Vaseline base was used on the lesions of the other side of the body twice daily.

Sponsors

Islamic Azad University, Pharmaceutical Sciences Branch
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients with the age between 18 to 50 years old; diagnosis of mild to moderate plaque type psoriasis on both sides of the body; not being under medical treatment for the past two months. Exclusion criteria: pregnancy; lactation; suffering from a major illness (such as cardiovascular disease, acute renal or liver disease, cancer or active malignancy); not having plaque psoriasis on both sides of the body.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Erythema, Thickness, Scaling. Timepoint: At the end of week 4. Method of measurement: Modified psoriasis area severity index (PASI) scores.;Tissue TNFa Level. Timepoint: At the end of Week 4. Method of measurement: Mouse anti-human TNFa (28401.111) monoclonal antibody.

Secondary

MeasureTime frame
Side effects. Timepoint: At the end of week 4. Method of measurement: Questionnaire, Photography, Scoring.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Farshad Hashemian

Islamic Azad University, Pharmaceutical Sciences Branch, Faculty of Pharmacy

hashemian.f@iaups.ac.ir+98 21 2264 0056

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026